Biocytogen 

Animal Models and Cell Lines

>Double Humanized Immune-Checkpoint Mice

B-hPD-1/hCTLA4 mice


Basic characteristics

1.png 


Targeting strategy


image.png

Protein expression analysis

2.png

Fig 1.Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1 /hCTLA4 mice were analyzed by flow cytometry.

Mouse CTLA4+ T cells were detectable in the WT mice, while human CTLA4+ T cells were detectable in the homozygous B-hPD-1 /hCTLA4 mice.


 3.png

Fig 2. Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1 /hCTLA4 mice were analyzed by flow cytometry.

Mouse PD-1+ T cells were detectable in the WT mice, while human PD-1+ T cells were detectable in the homozygous B-hPD-1 /hCTLA4 mice.


Combination therapy of PD-1(Keytruda) Ab and CTLA4(Yervoy) Ab


4.png

Fig 3. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hPD-1/hCTLA4 mice. Mice were grouped when the tumor size was approximately 150±50 mm3 (n=5). Anti-hCTLA4 antibody Yervoy and the anti-hPD-1 antibody Keytruda show modest inhibition of tumor growth. On the other hand, combination of anti-hCTLA4 antibody Yervoy and the anti-hPD-1 antibody Keytruda shows almost complete inhibition when compared to single Ab treatment. B-hPD-1/hCTLA4 mouse model is a powerful tool for in vivo evaluation of combination therapy efficacy for hPD-1 antibodies and hCTLA4 antibodies . (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.


 

【Return list】
* Contact Name
* Quantity
Telephone No.
Email
* Shipping address
Verification code captcha

© 2018 Beijing Biocytogen Co., Ltd. All rights reserved. Technical support: fast help cloud